Encube Ethicals Private Limited — Clindamycin Exporter Profile
Indian Pharmaceutical Exporter · #1 for Clindamycin · $14.6M export value · DGFT Verified
Encube Ethicals Private Limited is the #1 Indian exporter of Clindamycin with $14.6M in export value and 291 verified shipments. Encube Ethicals Private Limited holds a 16.1% market share in Clindamycin exports across 6 countries. The company exports 11 pharmaceutical products worth $57.5M across 9 therapeutic categories.
Encube Ethicals Private Limited — Clindamycin Export Profile: Buyers & Destinations
Where Does Encube Ethicals Private Limited Export Clindamycin?
| Country | Value | Shipments | Share |
|---|---|---|---|
| UNITED STATES | $9.7M | 278 | 94.6% |
| UNITED KINGDOM | $248.9K | 8 | 2.4% |
| MALTA | $150.6K | 4 | 1.5% |
| ISRAEL | $61.2K | 2 | 0.6% |
| UNITED ARAB EMIRATES | $44.7K | 2 | 0.4% |
| DENMARK | $43.0K | 2 | 0.4% |
Encube Ethicals Private Limited exports Clindamycin to 6 countries. The largest destination is UNITED STATES accounting for 94.6% of Encube Ethicals Private Limited's Clindamycin shipments, followed by UNITED KINGDOM (2.4%) and MALTA (1.5%). These destinations reflect Encube Ethicals Private Limited's established distribution network and regulatory approvals in key markets.
Who Are the Top Buyers of Clindamycin from Encube Ethicals Private Limited?
| Buyer | Country | Value | Orders |
|---|---|---|---|
| CARDINAL HEALTH | UNITED STATES | $3.3M | 94 |
| AIM RX 3PL, LLC | UNITED STATES | $2.2M | 73 |
| IPD, SC, USA | UNITED STATES | $2.2M | 61 |
| AIM RX 3PL LLC | UNITED STATES | $563.3K | 14 |
| IPD SC USA | UNITED STATES | $517.4K | 13 |
| MCKESSON THIRD PARTY LOGISTICS | UNITED STATES | $250.0K | 5 |
| MORNINGSIDE PHARMACEUTICALS LTD | UNITED KINGDOM | $219.9K | 7 |
| AIM RX 3PL,LLC | UNITED STATES | $200.8K | 7 |
| 15 INGRAM BLVD LA VERGNE TENNESSEE | UNITED STATES | $128.4K | 4 |
| NORTHSTAR DISTRIBUTION CE | UNITED STATES | $101.4K | 3 |
Encube Ethicals Private Limited supplies Clindamycin to 19 buyers globally. The largest buyer is CARDINAL HEALTH (UNITED STATES), followed by AIM RX 3PL, LLC (UNITED STATES) and IPD, SC, USA (UNITED STATES). These buyers represent pharmaceutical distributors, hospital groups, and government procurement agencies in their respective markets.
What Is India's Total Clindamycin Export Value and How Much Does Encube Ethicals Private Limited Contribute?
India exported $47.6M worth of Clindamycin through 7,242 shipments from 527 suppliers to 144 countries, serving 1,029 buyers globally. Encube Ethicals Private Limited contributes $14.6M to this total, accounting for 16.1% of India's Clindamycin exports. Encube Ethicals Private Limited ships Clindamycin to 6 countries through 19 buyers.
What Is the Average Shipment Value for Encube Ethicals Private Limited's Clindamycin Exports?
Encube Ethicals Private Limited's average Clindamycin shipment value is $50.0K per consignment, based on 291 shipments totaling $14.6M. The largest destination is UNITED STATES (94.6% of Encube Ethicals Private Limited's Clindamycin exports).
How Does Encube Ethicals Private Limited Compare to Other Indian Clindamycin Exporters?
Encube Ethicals Private Limited ranks #1 among 527 Indian Clindamycin exporters with a 16.1% market share. The top 3 exporters are ENCUBE ETHICALS PRIVATE LIMITED ($14.6M), AUROBINDO PHARMA LTD ($9.4M), GLENMARK PHARMACEUTICALS LIMITED ($4.7M). Encube Ethicals Private Limited processed 291 shipments to 6 destination countries.
What Clindamycin Formulations Does Encube Ethicals Private Limited Export?
| Product Description / Formulation | Value | Shipments |
|---|---|---|
| CLINDAMYCIN PHOSPHATE TOPICAL SOLUTION U | $586.2K | 19 |
| CLINDAMYCIN PHOSPHATE TOP. LOT.1% 60ML ( | $336.6K | 9 |
| CLINDAMYCIN (PHOSPHATE) GEL 1% 30GM (CLI | $263.3K | 7 |
| CLINDAMYCIN (PHOSPHATE) GEL 1% 60GM (CLI | $258.4K | 9 |
| CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDE | $250.0K | 5 |
| CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDEGEL, 1.2%/5% (45 GM) B.NO.3BF21 TO 3BF25 MFG DATE DEC 2023 EXP DATE NOV 2025NOS | $150.0K | 3 |
| CLINDAMYCIN PHOSPHATE TOPICAL LOTION, 1%,60ML B.NO.3CW27, 3CW26 MFG DATE DEC 2023 EXP DATE NOV 2025NOS | $150.0K | 3 |
| CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDEGEL, 1.2%/5% (45 GM) B.NO.4BF01 TO 4BF05 MFG DATE JAN 2024 EXP DATE DEC 2025NOS | $150.0K | 3 |
| CLINDAMYCIN PHOSPHATE TOPICAL LOTION 1%60ML (BATCH NO. 4CW39 4CW364CW384CW414CW434CW374CW454CW404CW444CW42 MFNOS | $150.0K | 3 |
| CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDEGEL,1.2%/5% (45 GM) B.No.4BF08,4BF10,4BF09,4BF11,4BF06,4BF07 MFG Dt.APR 2024 EX | $150.0K | 3 |
Encube Ethicals Private Limited exports 178 distinct Clindamycin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is CLINDAMYCIN PHOSPHATE TOPICAL SOLUTION U with 19 shipments worth $586.2K.
Regulatory Requirements: Exporting Clindamycin to Key Markets
What Encube Ethicals Private Limited must comply with to export Clindamycin to its top destination countries
United States — FDA
Approval Process
ANDA (Abbreviated New Drug Application) for generics. Indian manufacturing site must pass FDA pre-approval inspection. Drug Master File (DMF) required for APIs.
Timeline: 10–18 months for ANDA approval
GMP & Export Requirements
FDA cGMP compliance (21 CFR 210/211); facility inspection by FDA
Drug Listing with FDA; Export Certificate from CDSCO India; Import Alert screening via FDA PREDICT system
Note: Subject to FDA Import Alerts. Open Form 483 observations can block all exports from a facility.
United Kingdom — MHRA
Approval Process
Post-Brexit UK Marketing Authorisation via national procedure. Separate from EU approval since January 2021.
Timeline: 12–15 months
GMP & Export Requirements
UK GMP compliance; MHRA inspection of manufacturing site
Manufacturer Import Authorisation (MIA) held by UK importer; Qualified Person (QP) batch release
Note: Post-Brexit: EU GMP certificates no longer automatically valid in UK. Separate MHRA recognition required.
Regulatory information is provided for general reference based on publicly available guidelines. Requirements vary by formulation, dosage form, and therapeutic classification. Exporters should consult qualified regulatory affairs professionals for case-specific guidance.
How Does Encube Ethicals Private Limited Compare to Nearest Clindamycin Exporters?
Exporters ranked immediately above and below #1 by export value
| # | Supplier | Export Value | Shipments | Countries | Avg/Shipment |
|---|---|---|---|---|---|
| 1 | ENCUBE ETHICALS PRIVATE LIMITED ★ | $14.6M | 291 | 6 | $50.0K |
| 2 | AUROBINDO PHARMA LTD | $9.4M | 188 | 2 | $50.0K |
| 5 | GLENMARK PHARMACEUTICALS LIMITED | $4.7M | 199 | 6 | $23.6K |
Encube Ethicals Private Limited ranks #1 among 527 Indian Clindamycin exporters. Average shipment value of $50.0K compared to the market average of $90.3K. The closest competitors by value are AUROBINDO PHARMA LTD and GLENMARK PHARMACEUTICALS LIMITED.
Which Indian Ports Ship Clindamycin Exports?
| Port | Shipments | % Share |
|---|---|---|
| DELHI AIR CARGO ACC (INDEL4) | 1,184 | 16.3% |
| SAHAR AIR | 1,119 | 15.5% |
| SAHAR AIR CARGO ACC (INBOM4) | 966 | 13.3% |
| DELHI AIR | 674 | 9.3% |
| NHAVA SHEVA SEA (INNSA1) | 437 | 6.0% |
| JNPT/ NHAVA SHEVA SEA | 328 | 4.5% |
| Bombay Air | 309 | 4.3% |
| Delhi Air | 201 | 2.8% |
Geopolitical & Trade Policy Impact on Encube Ethicals Private Limited's Clindamycin Exports
Encube Ethicals' export operations are influenced by a complex interplay of geopolitical events and international trade policies. The ongoing Israel-Iran tensions have led to increased security risks in the Red Sea, prompting major shipping lines to implement 'Emergency Risk Surcharges' ranging from $250 to $500 per TEU. This escalation in shipping costs directly impacts Indian pharmaceutical exporters like Encube, potentially eroding profit margins and necessitating strategic adjustments in logistics and pricing strategies.
Conversely, the U.S.-China trade tensions have created opportunities for Indian pharmaceutical companies to capture a larger share of the U.S. market. Encube, with its FDA-approved facilities and established presence in the U.S., is well-positioned to leverage this shift. Additionally, the India-European Union Free Trade Agreement (FTA), concluded in January 2026, aims to eliminate tariffs on pharmaceuticals, thereby enhancing market access for Indian exporters. However, compliance with the EU's stringent regulatory standards, including the Falsified Medicines Directive, remains a critical factor for success in this market.
Encube Ethicals Private Limited — Regulatory Compliance & Quality Standards
Maintaining compliance with international regulatory standards is paramount for Encube Ethicals. The company's adherence to FDA, WHO, and EU Good Manufacturing Practices (GMP) ensures the quality and safety of its products, facilitating access to global markets. The evolving regulatory landscape, particularly in the EU, necessitates continuous investment in quality systems and processes. For instance, the EU's requirement for analytical testing of every batch at the port of destination can delay market entry by two to three months. Proactive engagement with regulatory bodies and investment in compliance infrastructure are essential for mitigating such challenges.
About Encube Ethicals Private Limited
Encube Ethicals Private Limited exports 11 products worth $57.5M. Beyond Clindamycin, top products include Diclofenac, Clotrimazole, Ketoconazole, Sodium, Miconazole. View the complete Encube Ethicals Private Limited profile for full portfolio analysis.
Market Intelligence
Latest developments and market context
Detailed market intelligence for Clindamycin — including regulatory updates, trade policy changes, and competitive landscape analysis — will be available in an upcoming update. This section will feature AI-researched insights from verified industry sources, government notifications, and market reports.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Product Matching: Clindamycin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
- 2.Supplier Identification: Encube Ethicals Private Limited matched across shipments using name normalization, accounting for company name formatting variations.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
- 4.Verified Records: This page is backed by 296 individual customs records matching Encube Ethicals Private Limited exporting Clindamycin, covering 178 formulations to 6 countries via 19 buyers.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
Global Coverage
Exports to 144+ countries, 1,029+ buyers
Expert-Reviewed
Analyzed by pharmaceutical trade specialists
Get Clindamycin Export Data from Encube Ethicals Private Limited
Access shipment-level details, pricing data, buyer connections, and competitive analysis for Encube Ethicals Private Limited's Clindamycin exports. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.
Encube Ethicals Private Limited
Full Company Profile →
11 products · $57.5M total trade · 9 categories
Clindamycin Stats
Company Overview
Top Products by Encube Ethicals Private Limited
Related Analysis
Need Detailed Export Data?
Access shipment-level records, pricing trends, and buyer contacts for Encube Ethicals Private Limited.
Request DemoView Pricing →Data Source
Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports for Clindamycin. For current shipment-level data, contact TransData Nexus.